These novel anthraquinone-derived compounds inhibit tNOX-NAD+-SIRT1 axis to induce apoptosis, highlighting the value of tNOX as a possible therapeutic target and implying future clinical use of these compounds in cancer treatment without considering p53 expression. Here, TP53 is linked to cancer.